Mr Buttula is a prominent investor and has over 30 years executive and director experience across many sectors of business including biotechnology. He brings considerable skills to Myopharm as it moves forward on executing its business plans.
Mr Buttula’s former roles include Managing Director of Lonsdale Securities and Investors Mutual, companies which he founded. He has served on numerous public listed company boards including Investorfirst, now HUB24 (ASX:HUB), and Non-Executive Director at Imugene (ASX IMU). Mr Buttula currently serves as Chairman at Rhythm Biosciences Limited (ASX: RHY), HITIQ Limited (ASX:HIQ) and OncoSil Medical Ltd (ASX:OSL).
Postal: P.O. Box 655
Which of the following group do you best fit?
Subscribe to our Email Alerts